EPAS1 mRNA in plasma from colorectal cancer patients is associated with poor outcome in advanced stages

23Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

The presence of free nucleic acids in plasma has been detected in cancer patients and is associated with poor prognosis. In the present study, the mRNA levels of three genes (EPAS1, KIAA0101 and UBE2D3) in plasma from colorectal cancer patients were analyzed. These genes were selected from a previous study of genomic profiles, discriminating between healthy controls and colorectal cancer patients. mRNA levels were analyzed by real-time PCR in the plasma of 154 patients with colorectal cancer. The association of plasma mRNA levels with clinicopathological parameters and patient survival were analyzed. High levels of EPAS1 in the plasma were associated with patients aged over 50 years, relapse of disease and patient mortality. When patients were divided into two groups, early (I and II) and advanced (III and IV) stages, an association was observed between high levels of EPAS1 mRNA and worse disease-free and overall survival in advanced stages. The expression of KIAA0101 and UBE2D3 was not associated with poor prognosis. Thus, our results suggest that EPAS1 mRNA levels may be an indicator of poor prognosis in colorectal cancer patients at advanced stages, obtained by a non-invasive method.

Cite

CITATION STYLE

APA

Mohammed, N., Rodriguez, M., Garcia, V., Garcia, J. M., Dominguez, G., Peña, C., … Bonilla, F. (2011). EPAS1 mRNA in plasma from colorectal cancer patients is associated with poor outcome in advanced stages. Oncology Letters, 2(4), 719–724. https://doi.org/10.3892/ol.2011.294

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free